Introduction
============

Acute kidney injury (AKI) is a common condition and, even when mild, is associated with mortality and morbidity \[[@B1]\]. During critical illness, AKI is most frequently observed in the settings of sepsis and after surgery \[[@B2]\]. In these contexts, fluid resuscitation (FR) is almost universally employed to maintain or increase cardiac output and organ perfusion. Creatinine-related variables and urine output are often targeted during resuscitation as surrogates of adequacy of organ perfusion in general and to prevent AKI. Understanding the relationship between FR, resuscitation goals and AKI is therefore important to develop a rational approach to FR strategies in acute illness.

From a renal standpoint, fluid therapy is aimed at restoring systemic blood pressure (a major determinant of renal perfusion pressure) and cardiac output (a pre-requisite for adequate renal blood flow (RBF)). Fluid administration aimed at restoring systemic blood pressure works mechanistically by increasing the preload and stroke volume. In hypovolaemia, fluid therapy restores right ventricular end-diastolic volume and is an essential first step in resuscitation. Unfortunately, conventional goals of FR and restoration of blood pressure, central venous pressure and/or urine output are only indirect measures of cardiac output and are much less indicative of the restoration of adequate organ blood flow. Similarly, the effects of critical illness, pre-existing chronic disease and pharmacotherapy can unpredictably alter physiological determinants of fluid responsiveness. These effects make the effects of FR variable in extent and duration, and make the assessment of adequacy of FR very challenging.

Evidence regarding FR and outcomes in critical illness and after major surgery can be divided into two categories. Firstly, a considerable body of evidence suggests that positive fluid balances are associated with increased postoperative complications \[[@B3],[@B4]\], while more conservative intravenous fluid administration strategies do not seem harmful to renal function \[[@B5]\]. Similarly in critical illness, more positive fluid balances have been associated with the development of AKI \[[@B6]\] and with worse out-comes if AKI develops \[[@B6],[@B7]\]. Secondly, use of goal-directed therapy (GDT) strategies for perioperative haemodynamic optimisation have been associated with decreased surgical complications \[[@B3],[@B8],[@B9]\] and reduced risk of postoperative AKI \[[@B10]\]. GDT strategies involve the use of intensive monitoring and specific haemodynamic targets to guide early aggressive fluid and/or vasoactive drug administration. While individually persuasive, collectively these two lines of evidence appear difficult to reconcile. On the one hand, fluid overload appears harmful overall, and to the kidney in particular; on the other hand, goal-directed FR reduces mortality, morbidity and renal dysfunction. The evidence base for both of these conclusions is strongest in surgery, and consequently perioperative resuscitation was chosen as the setting to best explore this issue.

This seeming conflict in evidence may be the cause of controversy surrounding the extent of FR in patients at risk of AKI. Yet, without knowledge of the relative timing of onset, duration and quantity of fluid given during GDT-FR compared with the current standard of care, it is impossible to gauge whether the apparent benefits of more conservative FR and those of goal-directed haemo-dynamic therapy are truly in opposition. Accordingly, we conducted a systematic literature review and meta-analysis of controlled trials of goal-directed resuscitation protocols in the settings of surgery. Our focus was on AKI and the quantity of fluid administered. We hypothesised that the beneficial effects of GDT on subsequent renal function are related to the amount of additional fluid given during GDT compared with control patients, treated according to the standard of care.

Methods
=======

Aims
----

We aimed to identify and review studies describing haemodynamically targeted FR during GDT for perioperative optimisation. In particular, we aimed to deter-mine whether such protocols have a beneficial effect on renal function and to what extent this treatment involves increased fluid administration in comparison with control groups treated according to the standard of care.

Electronic search strategy
--------------------------

We interrogated the MEDLINE electronic reference database using a combination of search terms (Figure [1](#F1){ref-type="fig"}). In addition, bibliographies of known systematic reviews and retrieved articles were examined for references of potential relevance. Our wide search terms defined a set of records containing randomised controlled trials (RCTs) of GDT in surgery; these abstracts were then manually examined to identify a subset of studies of potential relevance for manuscript retrieval. These publications were examined manually for accordance with our inclusion criteria. Additional checks were made to ensure none of these publications had been subject to retraction \[[@B11]\].

![**Search strategy**.](cc11345-1){#F1}

Study inclusion criteria
------------------------

### Population

We considered only patients undergoing major surgery. Studies involving mixed populations of critically ill patients were excluded.

### Intervention

GDT was defined as monitoring of physiological measurements related to adequacy of cardiac output, systemic oxygen delivery or ventricular preload and providing specific therapy to target normal or supra-normal values by FR alone or in combination with inotropic drugs. GDT was required to commence before or within 8 hours from commencement of surgery.

### Between-group comparisons

We considered studies that reported the effects of GDT versus standard haemodynamic therapy, with special emphasis on the comparisons of cumulative volumes of FR. We excluded RCTs with no difference in, or no description of, fluid management strategies between groups, RCTs comparing differing GDT protocols targeting the same physiological goal, or studies without predefined end points. A specific requirement was that studies needed to report a volumetric quantification of FR. We did not consider studies that examined the effect of differing maintenance fluid infusions in our main analysis.

### Outcome

Studies were required to report a renal outcome measure that defined AKI - this could be an absolute or relative change in serum creatinine or urea, a defined period of oliguria, a need for renal replacement therapy for AKI or some combination of these.

Data collection
---------------

We collected data on the study participants, the setting, the timing and duration of the intervention, the definition of AKI used, the method of physiological monitoring and the GDT protocol. We additionally examined indicators of study quality and reporting, including documentation of the method of randomisation, the extent of blinding and description of drop-outs based on the score proposed by Jadad and colleagues \[[@B12]\]. Finally, we documented the recorded volume of fluid administered and whether there were statistical differences in these quantities.

To assess the volumes of fluid administered in the treatment and control groups we calculated the difference in the mean or median total fluid volume delivered between groups. When a total was not reported, we summed the mean or median volumes of crystalloids, colloid and blood products given during the protocol period in the GDT and control groups to estimate the total fluid volume delivered in each group. We defined studies employing a larger volume of FR during GDT as those demonstrating a statistically significant difference between one or more types of fluid administered between groups during GDT. In addition, we excluded from our definition any studies where the difference in mean or median fluid administration during the GDT protocol period was \<500 ml, an arbitrary definition of a clinically insignificant difference in fluid administration between GDT and standard of care.

Statistical analysis
--------------------

Meta-analysis was performed using R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria \[[@B13]\]), utilising the packages *meta*, *metafor*and *rmeta*. As studies compared differing interventions in differing settings with differing measures of renal function, a random effects model was employed for all analyses. The effect of GDT in the meta-analysis of pooled studies was assessed by calculation of the odds ratio (OR) for AKI: OR \<1 favoured GDT over the control group. The 95% confidence intervals (CIs) of the ORs and two-sided *P*values were calculated. A statistical difference favouring or disfavouring GDT was considered to occur if the 95% CI failed to cross the OR = 1 line (equivalent to *P*\< 0.05).

Statistical heterogeneity \[[@B14]\] was assessed by calculation of the *I*^2^statistic and the Q-test \[[@B15],[@B16]\]. Heterogeneity or inconsistency was considered significant if *I*^2^was \>40% or if the *P*value for the Q-test was \<0.1 \[[@B17]\]. When heterogeneity was present we assessed for outlier studies using a Galbraith plot \[[@B18]\] and repeated the analysis excluding the most significant outlier \[[@B19]\]. Our meta-analysis was then repeated with subdivision by difference in volume of FR between the GDT and control groups and by use or nonuse of inotropes in GDT protocols.

Results
=======

Our search strategy on GDT in surgery identified 3,797 abstracts or articles from which we examined 53 potentially relevant manuscripts, finding 24 articles that met our inclusion criteria \[[@B20]-[@B43]\] (Figure [2](#F2){ref-type="fig"}). All studies were in adult patients. Among the surgical studies not meeting the inclusion criteria, three recent studies examined a more restrictive perioperative maintenance fluid infusion combined with the use of GDT in one or both groups to facilitate a conservative maintenance fluid regimen \[[@B44]-[@B46]\]. While these studies were not directly comparable with standard GDT trials, they are of relevance to a discussion of the interaction between GDT and fluid balance and we elected to examine these investigations in a separate analysis.

![**Search results for studies examining goal-directed therapy in surgery reporting a renal outcome**. GDT, goal-directed therapy.](cc11345-2){#F2}

The study details, population, size and quality indicators are presented in Table [1](#T1){ref-type="table"}; 15 of 24 studies had a Jadad score of 3. Blinding is inherently difficult when using a treatment intervention triggered by invasive monitoring, and most studies were unblinded or partially blinded; while the randomisation method and dropouts were generally well recorded. As most studies were of similar quality, we did not subdivide our analysis based on quality.

###### 

Study settings, size and quality of studies of fluid therapy

  Author                                                                                       Year   Country          Population                                                                                                  Number   Blinded   Randomised   Dropouts   Jadad score
  -------------------------------------------------------------------------------------------- ------ ---------------- ----------------------------------------------------------------------------------------------------------- -------- --------- ------------ ---------- -------------
  **Studies of GDT in surgery**                                                                                                                                                                                                                                               
  Challand and colleagues \[[@B25]\]                                                           2012   UK               Major open or laparoscopic colorectal surgery                                                               179      1         2            1          4
  Cecconi and colleagues \[[@B24]\]                                                            2011   Italy            Elective total hip arthroplasty                                                                             40       1         2            1          3
  Mayer and colleagues \[[@B35]\]                                                              2010   Germany          Major abdominal surgery                                                                                     60       1         2            1          3
  Jhanji and colleagues \[[@B31]\]                                                             2010   UK               Major gastrointestinal surgery                                                                              135      0         2            1          3
  Forget and colleagues \[[@B28]\]                                                             2010   Belgium          Major abdominal surgery                                                                                     82       0         1            1          2
  Benes and colleagues \[[@B21]\]                                                              2010   Czech Republic   High-risk elective intra-abdominal surgery                                                                  120      1         2            1          4
  Harten and colleagues \[[@B30]\]                                                             2008   UK - Scotland    Patients over the age of 50 undergoing emergency abdominal surgery                                          29       0         2            1          3
  Kapoor and colleagues \[[@B32]\]                                                             2008   India            Patients with EuroSCORE ≥3 undergoing coronary artery bypass surgery under cardiopulmonary bypass           30       0         2            1          3
  Donati and colleagues \[[@B27]\]                                                             2007   Italy            Major abdominal surgery                                                                                     135      0         2            1          3
  Lopes and colleagues \[[@B34]\]                                                              2007   Brazil           High-risk surgery                                                                                           33       0         2            1          3
  Chytra and colleagues \[[@B26]\]                                                             2006   Czech Republic   ICU admissions undergoing surgery for major trauma with expected blood loss \>2 l                           162      0         1            1          2
  Wakeling and colleagues \[[@B42]\]                                                           2006   UK               Colorectal resection                                                                                        128      0         2            1          3
  Noblett and colleagues \[[@B37]\]                                                            2006   UK               Elective colorectal resection                                                                               108      2         1            1          4
  Pearse and colleagues \[[@B38]\]                                                             2005   UK               High-risk general surgical patients                                                                         122      0         2            1          3
  McKendry and colleagues \[[@B36]\]                                                           2004   UK               Cardiac surgery                                                                                             174      0         2            1          3
  Gan and colleagues \[[@B29]\]                                                                2002   USA              Major elective surgery with an anticipated blood loss \>500 ml                                              100      0         2            1          3
  Bonazzi and colleagues \[[@B23]\]                                                            2002   Italy            Infrarenal abdominal aortic aneurysm repair                                                                 100      0         2            0          2
  Venn and colleagues \[[@B41]\]                                                               2002   UK               Proximal femoral fracture repair, age \>65                                                                  90       0         2            1          3
  Lobo and colleagues \[[@B33]\]                                                               2000   Brazil           Patients \>60 years old and/or with chronic diseases of vital organs who underwent major elective surgery   37       0         2            1          3
  Pölönen and colleagues \[[@B39]\]                                                            2000   Finland          Elective cardiac surgery                                                                                    403      0         2            1          3
  Wilson and colleagues \[[@B43]\]                                                             1999   UK               Patients undergoing major elective surgery who were at risk of developing postoperative complications       138      0         2            1          3
  Valentine and colleagues \[[@B40]\]                                                          1998   USA              Aortic surgery                                                                                              120      0         1            1          2
  Bender and colleagues \[[@B20]\]                                                             1997   USA              Elective vascular surgery                                                                                   104      0         1            1          2
  Bishop and colleagues \[[@B22]\]                                                             1995   USA              Surgery for major trauma                                                                                    125      0         1            1          2
  **Studies using GDT in surgery comparing restrictive vs. conservative maintenance fluids**                                                                                                                                                                                  
  Lobo and colleagues \[[@B46]\]                                                               2011   Brazil           High-risk elective surgery                                                                                  88       0         1            1          2
  Futier and colleagues \[[@B44]\]                                                             2011   France           Major abdominal surgery                                                                                     70       1         2            1          4
  Jammer and colleagues \[[@B45]\]                                                             2010   Norway           Open colorectal and lower intestinal surgery                                                                241      0         2            1          3

GDT, goal-directed therapy

Analysis of details of GDT interventions and renal outcome measures are presented in Table [2](#T2){ref-type="table"} and fluid administration during GDT is presented in Table [3](#T3){ref-type="table"}; further details of individual fluids administered in these studies are provided in Additional file [1](#S1){ref-type="supplementary-material"}. Diagnostic criteria for AKI varied widely from a defined increment in serum creatinine from baseline or oliguria over a specified duration to a need for renal replacement therapy (Table [2](#T2){ref-type="table"}); for two studies \[[@B37],[@B38]\] renal outcome data not in the original trial publication were reported in a previous meta-analysis \[[@B10]\]. Given the large variation in definition of AKI for studies of GDT in surgery, we performed a further sensitivity analysis considering only studies where AKI was defined as an elevation of creatinine from baseline of ≤100% or an absolute rise in serum creatinine of ≤200 μmol/l, representing studies using creatinine criteria for AKI thus including patients with less severe postoperative renal dysfunction (approximating RIFLE risk or injury AKI).

###### 

Goal-directed therapy strategies and renal outcome measures in studies

  Study                                                                                        Goal                                                                                            Timing of intervention                                              GDT monitor                  Intervention                                                                                                 Renal outcome                                                                                Significantly larger fluid in GDT
  -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------- -----------------------------------
  **Studies of GDT in surgery**                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Challand and colleagues \[[@B25]\]                                                           SV optimisation                                                                                 Intraoperative                                                      Oesophageal Doppler          SV-guided 200 ml HES 6% boluses                                                                              Creatinine increase to \>149% of baseline during first postoperative week                    Yes
  Cecconi and colleagues \[[@B24]\]                                                            Maximise SV and DO~2~I \>600 ml/min/m^2^                                                        Intraoperative and 1-hour postoperative                             FloTrac/Vigileo              SV-guided HES6% boluses ± dobutamine                                                                         Oliguria or AKI                                                                              Yes
  Mayer and colleagues \[[@B35]\]                                                              CI \>2.5 l/min/m^2^, SV variation \<12%                                                         Intraoperative                                                      FloTrac/Vigileo              250 to 500 ml colloid boluses ± dobutamine                                                                   UO \<500 ml/day or required dialysis for acute renal failure                                 No
  Jhanji and colleagues \[[@B31]\]                                                             SV optimisation                                                                                 For 8 hours postoperative                                           Lidco                        Gelatin 250 ml to optimise SV ± dopexamine 0.5 μg/kg/min                                                     AKIN criteria AKI                                                                            No
  Forget and colleagues \[[@B28]\]                                                             Pulse oximeter plethysmogram variability index \<13%                                            Intraoperative                                                      Pulse oximeter               250 ml colloid boluses                                                                                       Postoperative oliguria or RRT                                                                No
  Benes and colleagues \[[@B21]\]                                                              SV variation \<10%, CI \>2.5 l/min/m~2~                                                         Intraoperative                                                      FloTrac/Vigileo              3 ml/kg colloid boluses ± dobutamine                                                                         AKI by POSSUM scoring (increase in blood urea \>5 mmol/l from preoperative levels) or RRT    No
  Harten and colleagues \[[@B30]\]                                                             Pulse pressure variation \<10%                                                                  Intraoperative                                                      Lidco                        Boluses of 250 ml of 6% HES if pulse pressure variation \>10%                                                UO \<500 ml/day or increase in SCr \>30% from the preoperative level                         Yes
  Kapoor and colleagues \[[@B32]\]                                                             CVP \>6 mmHg, SVV \<10%, CI 2.5 to 4.2 l/min/m~2~, ScvO~2~\>70%                                 For 8 hours postoperative                                           FloTrac and ScvO~2~          Colloid boluses inotropes and blood per protocol                                                             Increase in SCr \>150 μmol/l, UO \<750 ml/24 hours                                           No^a^
  Donati and colleagues \[[@B27]\]                                                             O~2~ER \<27%                                                                                    Intraoperative to 24 hours                                          CVC, arterial line           Colloid boluses ± dobutamine                                                                                 SCr \>2 mg/dl or need for RRT                                                                No
  Lopes and colleagues \[[@B34]\]                                                              Pulse pressure variation \<10%                                                                  Intraoperative                                                      Arterial line                Colloid boluses 6% HES                                                                                       UO \<500 ml/day or serum creatinine \>170 μmol/l or dialysis for AKI                         Yes
  Chytra and colleagues \[[@B26]\]                                                             SV optimisation with FTc 0.35 to 0.4 seconds                                                    12 hours postoperative                                              Oesophageal Doppler          Colloid boluses 250 ml gelatin or 6% HES                                                                     Need for RRT                                                                                 Yes
  Wakeling and colleagues \[[@B42]\]                                                           SV optimisation                                                                                 Intraoperative                                                      Oesophageal Doppler          Gelatin colloid boluses                                                                                      UO \<500 ml/day or increase in SCr \>30% from the preoperative level                         Yes
  Noblett and colleagues \[[@B37]\]                                                            SV optimisation with FTc 0.35 to 0.4 seconds                                                    Intraoperative                                                      Oesophageal Doppler          6% HES boluses 7 or 3 ml/kg                                                                                  Increase in SCr or need for RRT                                                              No
  Pearse and colleagues \[[@B38]\]                                                             Optimise SV and DO~2~I \>600 ml/min/m^2^                                                        Postoperative 8 hours                                               Lidco                        Gelatin boluses to optimise SV ± dopexamine                                                                  Need for RRT                                                                                 Yes
  McKendry and colleagues \[[@B36]\]                                                           Stroke index \>35 ml/m^2^                                                                       Postoperative 4 hours                                               Oesophageal Doppler          200 ml boluses blood or colloid                                                                              Need for RRT                                                                                 Yes
  Gan and colleagues \[[@B29]\]                                                                SV optimisation with FTc 0.35 to 0.4 seconds                                                    Intraoperative                                                      Oesophageal Doppler          200 ml boluses of 6% HES                                                                                     UO \<500 ml/day or increase in SCr \>30% from the preoperative level                         Yes
  Bonazzi and colleagues \[[@B23]\]                                                            Cl\>3.0/min/m^2^, PAOP 10 to 18 mmHg, SVR\<1,450 dyne ×second/cm^5^, DO~2~I \>600 ml/min/m^2^   Preoperative to 2 days postoperative                                Pulmonary artery catheter    Fluid, blood, dobutamine                                                                                     Oliguria requiring high-dose frusemide or RRT                                                Yes
  Venn and colleagues \[[@B41]\]                                                               Two GDT groups: CVP \>14 mmHg or SV optimisation with FTc \>0.35 seconds                        Intraoperative                                                      CVC or oesophageal Doppler   Gelatin boluses 100 to 200 ml                                                                                UO \<500 ml/day or increase in SCr \>30% from the preoperative level                         Yes
  Lobo and colleagues \[[@B33]\]                                                               DO~2~I \>600 ml/min/m^2^                                                                        Intraoperative to24 hours                                           Pulmonary artery catheter    Fluids, blood, inotropes                                                                                     SCr \>3.5 mg/dl or UO \<500 ml/24 hours                                                      No
  Pölönen and colleagues \[[@B39]\]                                                            ScvO~2~\>70% lactate \<2 mM                                                                     8 hours postoperative                                               Pulmonary artery catheter    Fluids, blood, inotropes                                                                                     Increase in SCr \>1.7 mg/dl, UO \<750 ml/24 hours                                            No^a^
  Wilson and colleagues \[[@B43]\]                                                             DO~2~I \>600 ml/min/m^2^, PAOP \>12 mmHg                                                        Preoperative to 12 to 24 hours postoperative                        Pulmonary artery catheter    Fluids, blood dopexamine or adrenaline                                                                       UO \<0.5 ml/kg/hour for \>3 hours or 50% rise in SCr                                         No
  Valentine and colleagues \[[@B40]\]                                                          CI \>2.8 l/min/m^2^, PAOP 8 to 15 mmHg, SVR \<1,100 dyne × second/cm^5^                         \>14 hours preoperative                                             Pulmonary artery catheter    Fluids, dobutamine, vasodilators                                                                             Need for RRT or oliguria \>24 hours with doubling of SCr                                     Yes
  Bender and colleagues \[[@B20]\]                                                             CI \>2.8, PAOP 8 to 14 mmHg, SVR \<1,100 dyne × second/cm^5^                                    Preoperative to 16 hours postoperative                              Pulmonary artery catheter    Fluids, blood, dopamine, vasodilators                                                                        Increase in SCr \>1 mg/dl                                                                    Yes
  Bishop and colleagues \[[@B22]\]                                                             CI \>4.5 l/min/m^2^, DO~2~I \>760 ml/min/m^2^, VO~2~I \>166 ml/min/m^2^                         Attain goal within 24 hours of admission and maintain for48 hours   Pulmonary artery catheter    Fluids, blood, dobutamine, vasodilators                                                                      SCr \>2 mg/dl or twice baseline in CKD                                                       Yes
  **Studies using GDT in surgery comparing restrictive vs. conservative maintenance fluids**                                                                                                                                                                                                                                                                                                                                                                                                              
  Lobo and colleagues \[[@B46]\]                                                               DO2I \>600 ml/min/m^2^                                                                          Intraoperative and 8 hours postoperative                            Lidco                        SV-guided gelatin bolus ± dobutamine in both groups. Maintenance fluid 4 vs. 12 ml/kg/hour                   SCr ×2 upper limit of normal                                                                 Yes
  Futier and colleagues \[[@B44]\]                                                             Variation in peak aortic flow velocity (ΔPV) \<13%                                              Intraoperative                                                      Oesophageal Doppler          ΔPV-guided boluses of 6% HES in both groups. Maintenance crystalloid 6 vs. 12 ml/kg/hour                     UO \<500 ml/day or increase in SCr \>30% from the preoperative level or need for acute RRT   Yes
  Jammer and colleagues \[[@B45]\]                                                             ScVO~2~\>75%                                                                                    Intraoperative                                                      CVC                          Colloid boluses 3 ml/kg HES in GDT group. Maintenance fluid 100 ml/hour in GDT vs. 800 ml/hour in controls   SCr increase \>33%                                                                           Yes

Statistically significant greater fluid administration in goal-directed therapy (GDT) deemed clinically insignificant (difference \<500 ml). AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CI, cardiac index; CKD, chronic kidney disease; CVP, central venous pressure; CVC, central venous catheter; DO~2~I, oxygen delivery index; FTc, corrected flow time; HES, hydroxyethyl starch; O~2~ER, oxygen extraction ratio; PAOP, pulmonary artery occlusion pressure; POSSUM, Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity; RRT, renal replacement therapy; sCr, serum creatinine; ScvO~2~, central venous oxygen saturation; SV, stroke volume; SVR, stroke volume ratio; SVV, stroke volume variation; UO, urine output; VO~2~I, oxygen consumption index. FloTrac, Edwards Lifesciences, Irvine, CA, USA; Lidco, LiDCO Group, London, UK; Vigileo, Edwards Lifesciences, Irvine, CA, USA. ^a^Statistically, but not clinically significantly larger FR in GDT group (\<500 ml).

###### 

Total fluid administration in studies of perioperative goal-directed fluid therapy

                                                                                                                                         Total fluid resuscitation during intervention (ml)                   
  ------------------------------------------------------------------------------------------- ------ ----------------------------------- ---------------------------------------------------- --------------- ------------
  **Studies of GDT in surgery**                                                                                                                                                                               
  Challand and colleagues \[[@B25]\]                                                          2012   Operation                           **5,278**                                            **4,046**       **1,232**
  Cecconi and colleagues \[[@B24]\]                                                           2011   Operation + 1 hour                  **6,032**                                            **2,635**       **3,397**
  Mayer and colleagues \[[@B35]\]                                                             2010   Operation                           4,528                                                4,494           34
  Jhanji and colleagues \[[@B31]\] without dopexamine                                         2010   8 hours                             4,892                                                4,351           541
  Jhanji and colleagues \[[@B31]\] with dopexamine                                                                                       4,868                                                                517
  Forget and colleagues \[[@B28]\]                                                            2010   Operation                           2,394                                                2,918           -524
  Benes and colleagues \[[@B21]\]                                                             2010   Operation                           3,746                                                3,729           17
  Harten and colleagues \[[@B30]\]                                                            2008   Operation                           **3,500**                                            **3,000**       **500**
  Kapoor and colleagues \[[@B32]\]                                                            2008   Operation + 8 hours                 **330^a^**                                           **80^a^**       **250^b^**
  Donati and colleagues \[[@B27]\]                                                            2007   Operation + 24 hours                4,391                                                4,285           106
  Lopes and colleagues \[[@B34]\]                                                             2007   Operation                           **4,618**                                            **1,694**       **2,924**
  Chytra and colleagues \[[@B26]\]                                                            2006   8 hours                             **4,516**                                            **3,649**       **867**
  Wakeling and colleagues \[[@B42]\]                                                          2006   Operation                           **5,000**                                            **4,500**       **500**
  Noblett and colleagues \[[@B37]\]                                                           2006   Operation                           3,638                                                3,834           -196
  Pearse and colleagues \[[@B38]\]                                                            2005   8 hours                             **2,962**                                            **2,164**       **798**
  McKendry and colleagues \[[@B36]\]                                                          2004   4 hours                             **2,020**                                            **681**         **1,339**
  Gan and colleagues \[[@B29]\]                                                               2002   Operation                           **5,420**                                            **4,775**       **645**
  Bonazzi and colleagues \[[@B23]\]                                                           2002   Operation to postoperative day 2    **11,130**                                           **9,130**       **2,000**
  Venn and colleagues \[[@B41]\]                                                              2002   Operation                           **2,655**                                            **2,075**       **580**
  Lobo and colleagues \[[@B33]\]                                                              2000   24 hours                            6,600                                                7,200           -600
  Pölönen and colleagues \[[@B39]\]                                                           2000   8 hours                             **3,193**                                            **2,772**       **421^b^**
  Wilson and colleagues \[[@B43]\]                                                            1999   Operation + 12 hours                3,200                                                3,500           -300
  Valentine and colleagues \[[@B40]\]                                                         1998   14 hours preoperative + operation   **8,650**                                            **6,710**       **1,940**
  Bender and colleagues \[[@B20]\]                                                            1997   Operation + 16 hours                **5,137**                                            **3,789**       **1,348**
  Bishop and colleagues \[[@B22]\]                                                            1995   Preoperative and intraoperative     **21,975^c^**                                        **10,876^c^**   **11,099**
  **Studies using GDT in surgery comparing restrictive vs. conservative maintenance fluid**                                                                                                                   
  Lobo and colleagues \[[@B46]\]                                                              2011   Operation + 8 hours                 3,517                                                5,250           -1,733
  Futier and colleagues \[[@B44]\]                                                            2011   Operation                           3,380                                                5,588           -2,208
  Jammer and colleagues \[[@B45]\]                                                            2010   Operation                           3,869                                                6,491           -2,622

Approximate mean or median fluid volume per patient was approximated from data provided in individual studies (see Addition File 1 for further information). Any statistically significantly greater administration of a component of fluid resuscitation in goal-directed therapy (GDT) over the control group is highlighted in bold. ^a^Extra volume above maintenance fluids 500 ml/m^2^/day documented. ^b^Statistically significant greater fluid administration in GDT deemed clinically insignificant (difference \<500 ml). ^c^Cumulative fluid balance in study through to end of surgery.

Goal-directed therapy in surgery
--------------------------------

Of the 24 included studies, 16 reported a statistically significant greater quantity of colloid, crystalloid or total fluid administered during GDT. In two studies the difference in fluid administration was statistically significant but the total difference in FR between the GDT and control groups during the study period was small (+241 ml and +450 ml), so these studies were reallocated to the equivalent volume of FR with GDT group \[[@B32],[@B39]\]. Fourteen studies were thus deemed to involve a greater volume of FR during GDT, their median difference in FR between the GDT and control groups being +1,247 ml (range 500 to 11,099 ml). In the 10 studies categorised as having no greater volume of total FR during GDT, the median difference in FR was 10 ml (range -600 to +529 ml). Among all 24 studies, the median difference in FR was +555 ml.

Overall, 13 studies employed inotropic drugs in some or all patients in the GDT group, 10 studies did not use inotropic drugs, and one study had two treatment arms - one arm involving infusion of dopexamine in addition to stroke-volume-directed fluid boluses, and the other arm involving stroke-volume-guided therapy alone \[[@B31]\] (Table [2](#T2){ref-type="table"}). In the meta-analysis this study was included as a single study in the overall analysis and in the analysis based on fluid therapy, but was treated as two studies when dividing studies on the basis of inotropic use (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}).

![**Meta-analysis of goal-directed therapy in surgery and risk of acute kidney injury**. Meta-analysis of goal-directed therapy (GDT) in surgery and risk of acute kidney injury (AKI) using a random effects (RE) model. CI, confidence interval.](cc11345-3){#F3}

###### 

Meta-analysis for prediction of acute kidney injury with measures of heterogeneity

  Comparison                                                                                                                          Number of studies   Odds ratio (95% CI)   *p*      *τ* ^2^   Q-statistic *P*value   *I*^2^(%)   *H* ^2^
  ----------------------------------------------------------------------------------------------------------------------------------- ------------------- --------------------- -------- --------- ---------------------- ----------- ---------
  All studies conventional fluid strategies                                                                                           24                  0.59 (0.39 to 0.89)   0.013    0.19      0.21                   20.2        1.25
  GDT involved no clinically significantly greater fluid administration                                                               10                  0.47 (0.29 to 0.76)   0.0049   0         0.73                   0           1.0
  Clinically significantly more fluids administered with GDT                                                                          14                  0.70 (0.35 to 1.41)   0.32     0.60      0.09                   39.4        1.65
  Clinically significantly more fluids administered with GDT excluding outlier study                                                  13                  0.88 (0.49 to 1.58)   0.68     0.18      0.44                   16.7        1.19
  All studies conventional fluid strategies, no inotropes                                                                             11^a^               0.55 (0.24 to 1.26)   0.16     0.97      0.03                   52.5        2.11
  All studies conventional fluid strategies, no inotropes excluding outlier study                                                     10^a^               0.75 (0.37 to 1.53)   0.43     0.38      0.19                   30.8        1.45
  All studies conventional fluid strategies - inotropes in GDT                                                                        14^a^               0.52 (0.34 to 0.80)   0.0030   0         0.87                   0           1.0
  No clinically significant greater fluid administration, no inotropes                                                                3^a^                0.47 (0.13 to 1.75)   0.25     0.51      0.23                   37.3        1.59
  No clinically significant greater fluid administration, inotropes in GDT                                                            8^a^                0.46 (0.27 to 0.77)   0.0036   0         0.85                   0           1.0
  Clinically significant more fluids administered with GDT, no inotropes                                                              8                   0.55 (0.18 to 1.68)   0.30     1.46      0.02                   60.5        2.53
  Clinically significant more fluids administered with GDT, no inotropes excluding outlier study                                      7                   1.0 (0.46 to 2.17)    0.99     0.19      0.26                   17.2        1.21
  Clinically significant more fluids administered with GDT, inotropes in GDT                                                          6                   0.73 (0.31 to 1.69)   0.46     0.11      0.61                   8.9         1.1
  Creatinine-based definition of AKI excluding outlier study                                                                          12                  0.61 (0.36 to 1.02)   0.06     0.20      0.23                   26.6        1.36
  Creatinine-based definition of AKI, GDT involved no clinically significantly greater fluid administration excluding outlier study   5                   0.41 (0.23 to 0.72)   0.002    0         0.83                   0           1.0
  Creatinine-based definition of AKI, clinically significantly more fluids administered with GDT excluding outlier study              7                   0.90 (0.41 to 1.97)   0.80     0.35      0.18                   33.3        1.5
  GDT to assist restrictive fluid strategy in treatment arm                                                                           3                   1.68 (0.69 to 4.12)   0.26     0         0.29                   0           1.0

Statistical analysis - random effects model. AKI, acute kidney injury; CI, confidence interval. ^a^One study presented data on goal-directed therapy (GDT) with and without inotropic therapy \[[@B31]\]. Data from these groups were considered as separate studies, dividing on the basis of use/nonuse of inotropes in GDT.

Overall, GDT in surgery was associated with a significantly lower incidence of AKI (OR = 0.59, 95% CI = 0.39 to 0.89, *P*= 0.013; 24 studies, *n*= 2,763 patients) (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}). When subdividing by larger versus equivalent fluid administered during GDT, studies involving equivalent overall fluid therapy were associated with a lower incidence of AKI (OR = 0.47, 95% CI = 0.29 to 0.76, *P*= 0.0049; 10 studies, *n*= 1,268 patients) (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}) whereas studies categorised as involving larger fluid administration during GDT were not associated with lower incidence (OR = 0.70, 95% CI = 0.35 to 1.41, *P*= 0.32; 13 studies, *n*= 1,462 patients); one study was excluded for heterogeneity \[[@B34]\].

Goal-directed therapy and inotropic drug use in surgery
-------------------------------------------------------

Inotropic drug use in GDT patients was associated with a reduction in the incidence of postoperative AKI (OR = 0.52, 95% CI = 0.34 to 0.80, *P*= 0.003; 14 studies, *n*= 1,634 patients) (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}) compared with studies not involving inotropic drugs (OR = 0.75, 95% CI = 0.37 to 1.53, *P*= 0.43; 10 studies, *n*= 1,016 patients); one study was excluded for heterogeneity \[[@B34]\] (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}). The lowest incidence of postoperative AKI occurred in patients with equivalent total fluid delivery in a protocol involving inotropic drugs (OR = 0.46, 95% CI = 0.27 to 0.76, *P*= 0.0036; eight studies, *n*= 1,033 patients) (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}); however, only a small number of studies (three studies, 280 patients) without use of inotropic drugs had equivalent total fluid delivery in the treatment group, so the effect in this group was difficult to assess.

Goal-directed therapy involving restrictive fluid strategies in surgery
-----------------------------------------------------------------------

Three studies involving GDT and more restrictive fluid management were identified (Table [1](#T1){ref-type="table"}). Two of these studies involved GDT in both groups with differing maintenance fluid rates during surgery, while one study involved GDT only in the more restrictive fluid infusion group (Table [2](#T2){ref-type="table"}). The median difference in fluid delivered was 2,208 ml lower (range -1,733 to -2,622 ml) in the treatment group (Table [3](#T3){ref-type="table"}). In these three studies there was no clear statistical association between the volume of fluid therapy delivered and AKI (OR for AKI in treatment group = 1.68, 95% CI = 0.69 to 4.12, *P*= 0.26) (Figure [4](#F4){ref-type="fig"} and Table [4](#T4){ref-type="table"}).

![**Meta-analysis of restrictive fluid management with goal-directed therapy and risk of acute kidney injury**. Meta-analysis of restrictive fluid management in conjunction with goal-directed therapy and risk of acute kidney injury (AKI) using a random effects (RE) model. CI, confidence interval.](cc11345-4){#F4}

Goal-directed therapy in surgery: sensitivity analysis
------------------------------------------------------

We identified 13 studies that used more sensitive and comparable creatinine-based definitions of AKI \[[@B20],[@B22],[@B25],[@B27],[@B29]-[@B32],[@B34],[@B39],[@B41]-[@B43]\], one of which \[[@B34]\] was excluded from meta-analyses due to heterogeneity. In this set of trials the association between GDT and protection for AKI was just nonsignificant (OR = 0.61, 95% CI = 0.36 to 1.02, *P*= 0.006; 12 studies, *n*= 1,606 patients) (Table [4](#T4){ref-type="table"}). However, the risk of AKI was significantly lower in studies with no significant difference in total fluid administration (OR = 0.41, 95% CI = 0.23 to 0.71, *P*= 0.002; five studies, *n*= 861 patients) (Table [4](#T4){ref-type="table"}), while no difference was observed in studies with greater total fluid administration in GDT (OR = 0.90, 95% CI = 0.41 to 1.97, *P*= 0.80; seven studies, *n*= 745 patients) (Table [4](#T4){ref-type="table"}).

Discussion
==========

Key findings
------------

In this review we have examined the evidence for the use of FR in improving renal outcomes during major surgery. We found that, on average, protocolised GDT did not result in significantly larger volumes of fluid therapy being administered when compared with standard management. Furthermore, most of the protection from AKI seemed to occur in studies reporting equivalent total quantity of fluid administration between groups. From this evidence, it is difficult to ascribe benefits of GDT simply to the provision of greater volumes of intravenous fluids to hypovolaemic patients, suggesting any effect actually derived from other aspects of care. Our findings were similar when only studies using more sensitive creatinine-based definitions of AKI were examined in a sensitivity analysis. Use of inotropes seemed to be associated with lower incidence of AKI with GDT and with the delivery of equivalent amounts of FR.

Relationship to previous studies
--------------------------------

Conventionally, a reduction in RBF and renal ischaemia have been regarded central to the pathogenesis of AKI in critical illness \[[@B47]\]; however, the situation is likely to be more complex \[[@B48]\]. In animal models, AKI has been reported when cardiac output was preserved or elevated \[[@B49]\], and subtotal (90%) occlusion of the renal arteries did not lead to prolonged AKI \[[@B50]\]. Furthermore, cardiac arrest and warm renal ischaemia in humans only lead to significant AKI in the presence of severe post-resuscitation disease and cardiogenic shock \[[@B51]\]. These observations infer that local and systemic inflammatory responses, changes in intra-RBF distribution, microcirculatory dysfunction and glomerular haemodynamics may all account for loss of kidney function, even in the presence of maintained or increased RBF.

Fluid administration has been shown to augment both cardiac output and RBF without an overall increase in renal oxygen delivery \[[@B52]\], while FR in an experimental model of haemorrhagic shock can restore blood pressure and cardiac output without recovery of renal tissue oxygen tension \[[@B53]\]. Finally, even when renal oxygen delivery is reduced, increased oxygen extraction may maintain renal oxygen consumption \[[@B54]\] - suggesting that increasing renal oxygen delivery by increasing cardiac output may not avert AKI.

Measurements of cardiac output are rarely made until critical illness is established, RBF measurements are not clinically available, and fluid therapy is routinely targeted to the treatment of arterial hypotension. Absolute or relative hypotension is considered a significant risk factor for the development of AKI \[[@B55],[@B56]\], and lower blood pressure has been associated with the progression of AKI in sepsis \[[@B57]\]. However, hypotension may be related to low cardiac output, systemic vasodilation or a combination of both; and in the setting of systemic hypotension, RBF may be reduced, elevated or unchanged. As hypotension will only respond to FR if a meaningful increase in cardiac output can be obtained, this response may only be partial or transient in the context of systemic vasodilatation. The RBF effect of FR for hypotension might thus be significant or negligible depending on the context. Bedside physiological measurements such as blood pressure and urine output will be even more indirectly related to the pathogenesis of AKI, although they are routine triggers for FR.

Significance of study findings
------------------------------

Any potential benefits of FR must be weighed against the consequences of fluid accumulation. In acute illness, exogenous fluid replacement almost inevitably leads to positive fluid balances. Additionally, the critically ill are particularly susceptible to fluid overload \[[@B5]\]. Physio-logically, fluid overload results in tissue oedema that may contribute to progressive organ dysfunction. Liberal perioperative fluid strategies, involving large positive fluid balances, have been associated with increased complications after surgery \[[@B3],[@B4],[@B58]\]. Importantly, as an encapsulated organ the kidney is itself particularly affected by fluid congestion, because raised venous and intra-capsular pressures cause significant decreases in RBF and the glomerular filtration rate \[[@B59]\]. Studies examining liberal versus more conservative fluid management during surgery have failed to demonstrate an increase in AKI in patients receiving less fluid. Instead, recent analysis of results from the Fluid and Catheter Treatment Trial has shown that pursuing an even fluid balance strategy in patients with acute lung injury was associated with a lower incidence of AKI after allowing for the dilutional effect of positive fluid balances on serum creatinine concentration \[[@B60]\].

GDT may thus be beneficial not only by providing extra fluid when it is specifically indicated, but also by allowing earlier and guided use of fluids while preventing the delivery of unnecessary fluid when specific and objective haemodynamic targets are met. Seen in this light, appropriate use of GDT is in harmony, rather than in conflict, with more restrictive approaches to perioperative fluid therapy.

We identified three studies that fell outside the criteria for inclusion in our main analysis where GDT was used in conjunction with fluid restriction \[[@B44]-[@B46]\]. These studies moved beyond fluid optimisation using GDT to actively minimise perioperative maintenance fluid administration, resulting in significantly smaller fluid administration than standard care (Table [3](#T3){ref-type="table"}). No clear association was found between postoperative AKI and more restrictive fluid balances. A possible trend toward increased incidence of AKI with fluid restriction was seen, but there was significant heterogeneity between a small number of studies. In addition, relative haemodilution in control groups might be expected to artefactually lower the incidence of AKI, which was defined by small rises in serum creatinine. Given that avoidance of fluid overload may improve wider postoperative outcomes, and that GDT appears to protect against AKI when compared with conventional fluid management, the use of GDT strategies to facilitate more restrictive perioperative fluid therapy while avoiding covert hypovolaemia merits further examination in larger trials.

Low-dose inotropes have been associated with better postoperative outcomes when used in perioperative GDT \[[@B61]\]. In our meta-analysis, use of inotropes in GDT was associated with a decreased risk of postoperative AKI - a finding described previously \[[@B10]\]. Without specific trials, however, it is difficult to dissect the relative contributions of inotropy and fluid management on renal outcomes. We found that trials using inotropes in GDT and similar volumes of fluid therapy to controls were associated with the best renal outcomes, while excess fluid and no inotropes were associated with the worst renal outcomes. It is difficult to assess the relative contributions of FR and inotropes, but a synergistic effect is likely; so that goal-directed FR may allow optimal use of inotropic drugs, while inotropic drugs may maximise the haemodynamic effect of fluids and reduce the risk of fluid overload. Notably, an important physiological consequence of increased cardiac contractility is a decrease in right atrial pressure, potentially a beneficial effect limiting the increase in venous pressure with FR.

Are these findings generalisable beyond the context of major surgery? Sepsis is the leading cause of AKI in the ICU and shares many features with systemic inflammatory response after major surgery. In septic shock, even though patients tend to have high cardiac outputs, insensible or distributive fluid losses are common and FR may be required acutely. However, increased capillary permeability makes septic patients particularly prone to generalised tissue oedema and the adverse effects of fluid overload. Historically, approaches targeting supranormal levels of cardiac output and oxygen delivery in patients with established critical illness (including many patients with severe sepsis) have been nonbeneficial \[[@B62]\] or harmful \[[@B63]\]. More recently, treatment protocols immediately after presentation have demonstrated that targeting central venous oxygen saturation may improve survival in septic shock \[[@B64]\]. However, the specific effect of goal-directed resuscitation on renal function was not explicitly examined.

Applying a similar search strategy to that employed in the present systematic review to locate studies examining GDT for the acute treatment of septic shock, we only identified two articles documenting a renal outcome \[[@B65],[@B66]\] - only one of which was in adult patients, precluding a useful meta-analysis in this population. Both of these studies showed a beneficial effect of GDT on renal as well as other outcomes. Significantly, in both studies GDT was associated with earlier FR in at a higher flow rate than standard care, but the overall quantity of FR did not differ between GDT and standard care - suggesting that, in septic shock, early, targeted, therapy may restore haemodynamics and spare later fluid requirements. The same effect - early GDT actually being associated with similar fluid balances to controls over a longer period of treatment - was also observed by Rivers and colleagues in their landmark, although controversial, single-centre study of early GDT in septic shock \[[@B64]\]. By contrast, in the recent FEAST study of fluid management in children presenting with severe sepsis in Kenya, Tanzania and Uganda, rapid fluid bolus volume expansion was associated with significant harm \[[@B67]\]; importantly, however, fluid therapy in the FEAST study was not guided by any form of invasive haemodynamic monitoring. Therefore, in the setting of septic shock as well as surgery, goal-directed haemodynamic resuscitation may be beneficial to the kidney and other organs by targeting FR only to those patients that require it, and avoiding FR in those that do not. At present, however, evidence to guide choices in FR for septic shock remains very limited.

Strengths and limitations of review findings
--------------------------------------------

The meta-analyses performed in this review provide a basis for discussion of the benefits of FR on renal function in the critically ill. Our search was confined to the Pubmed electronic database and it is possible that relevant studies were missed; however, similar meta-analyses with a wider database search identified a similar set of publications \[[@B8],[@B10]\], while inclusion in Pubmed publications should ensure original studies were subject to independent peer review. Studies varied widely in populations, outcome measures and methodology, and conclusions from these data can only be regarded as hypothesis forming - although our results were essentially unchanged when considering only studies with more similar definitions of AKI. GDT protocols are complex and it is difficult to attribute benefit to specific components of each strategy. We can hypothesise that GDT results in timelier FR for patients who require it, even if the total volume of FR within a trial does not differ from the standard of care. While this is probably true considering the nature of GDT, data provided in the surgical trials we considered generally did not include timing of fluids within the study period, so we had no capacity to examine this important question in our analysis.

We did not assess the formulation of intravenous fluids in these studies. This is a complex issue of considerable clinical significance. However, none of the studies we examined set out to specifically compare differing formulations of intravenous fluid, and a variety of intravenous fluids were used in the treatment and control groups in these studies. Individual patient data would be required to explore the effect of fluid formulation on renal outcomes in these studies. It is of course possible that higher volume fluid administration is associated with a larger volume of colloid exposure, potentially associated with harm to the kidney countering the benefits of GDT, but assessing the size of any effect will be very difficult. Major multicentre randomised trials comparing the effect of colloid versus crystalloids for FR in intensive care are nearing publication \[[@B68],[@B69]\] and high-quality data regarding the formulation of FR and outcomes should shortly be available. When these data are available we will be in a much better position to assess the interaction between the volume of FR, the composition of intra-venous fluids and AKI.

Our assessments of overall fluid volumes administered between groups in these studies are based on the mean or median values provided in the articles; they are therefore imprecise and do not provide information on the fluid balance, timing of fluid administration or rate of fluid administration. However, even though the exact fluid quantities and their clinical significance could be argued, we feel the general conclusion that perioperative GDT does not, overall, result in much additional intravenous fluid being administered is supported by the studies identified. We considered fluid administration rather than fluid balance, because fluid balances during GDT were only reported in a small number of studies. Three large multicentre RCTs examining the effect of GDT in sepsis (ProCESS \[[@B70]\], ARISE \[[@B71]\] and ProMISe \[[@B72]\]) and another RCT examining perioperative GDT in high-risk surgery (OPTIMISE \[[@B73]\]) are ongoing. Our level of evidence to guide fluid therapy in complex, acute unwell patients should therefore increase in the next 3 to 4 years. In the interim, current evidence suggests that fluid management that rapidly recognises and treats hypovolaemia while avoiding inappropriate fluid loading may be optimal for renal function and wider clinical outcomes.

Conclusions
===========

Goal-directed haemodynamic therapies involving guided administration of intravenous fluids are associated with decreased incidence of AKI in the setting of major surgery. Evidence in sepsis is presently inconclusive. Crucially, the benefit of these targeted haemodynamic interventions does not seem to be dependent on the amount of fluid administered. On the contrary, GDT seems to achieve better kidney protection when delivering equivalent amounts of FR, perhaps by providing fluid earlier, faster and with the support of inotropic drugs, thus minimizing the harmful effects of fluid overload.
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